159.48 0.00 (0.00%)
After hours: 5:58PM EDT
|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||159.26 - 164.68|
|52 Week Range||142.81 - 256.80|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2018 - May 11, 2018|
|Forward Dividend & Yield||2.88 (1.76%)|
|1y Target Est||215.95|
Teva Pharmaceuticals (TEVA) reported a GAAP (generally accepted accounting principles) operating loss of $13 billion in fiscal 4Q17, which it reported on February 8, 2018. This difference was the result of significant impairment charges related to Teva’s US generics business in fiscal 4Q17. In fiscal 4Q17, Teva recorded a non-GAAP adjustment of $15.3 billion, ~$11 billion of which was due to the impairment of goodwill related to the company’s US generics business.
THOUSAND OAKS, Calif., March 23, 2018 /PRNewswire/ -- Amgen (AMGN) and Allergan plc. (AGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of ABP 980, a biosimilar to Herceptin® (trastuzumab). ABP 980 has been recommended for approval for the treatment of the same three types of cancer as Herceptin is approved for in the European Union (EU), including HER2-positive metastatic breast cancer, HER2-positive early breast cancer and HER2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding AGN totaled $2.10 billion.
-- An estimated 7.4 million people in China are living with this sight-threatening condition i,ii,iii -- DUBLIN , March 22, 2018 /PRNewswire/ -- Today, Allergan plc (NYSE:AGN) announces the launch of Ozurdex ...
This weekend's Barron's shows why one key analyst has a contrarian view on the direction that health care costs are headed. Other featured articles examine the prospects for pharmaceutical company facing ...
Looks can be deceiving when it comes to the drugmaker Allergan. New competition to its top product, Botox, and the surprise loss of patent exclusivity for its second biggest, the dry-eye treatment Restasis, have left investors with worry lines. The valuation is low enough that most of the bad news surrounding Allergan appear already priced in.
Drugmaker Mylan N.V. (NASDAQ:MYL) has garnered quite a bit of bullish attention since the beginning of the month. MYL stock is up more than 4% so far in March, beating the benchmark S&P 500 Index’s gain of about 1.4%. First, Mylan reported better than expected earnings on March 1 and it announced a competitor to Allergan plc Ordinary Sharess (NYSE:AGN) Botox treatment.
Allergan plc Ordinary Shares (NYSE: AGN ) continued its two-week, 16-percent rebound Wednesday, and RBC Capital Markets anticipates 28 percent of additional upside . The Rating Analyst Randall Stanicky ...
Brent Saunders spoke at the Barclays healthcare conference, a few weeks after Mylan and Revance Therapeutics said they were teaming up on a proposed biosimilar of Allergan's Botox.
In 4Q17, Merck’s (MRK) Emend generated revenues of $143 million, which reflected a ~1% decline on a YoY (year-over-year) basis but a 4% rise on a QoQ (quarter-over-quarter) basis. In 4Q17, in the US and in international markets, Emend reported revenues of $85 million and $58 million, respectively, compared with $90 million and $53 million in 4Q16, which reflected a ~6% decline and an 8% rise, respectively, YoY. In fiscal 2017, Emend generated revenues of $556 million, compared with $549 million in 2016, which reflected a ~1% rise YoY.
The Zacks Analyst Blog Highlights: Lockheed Martin, Allergan, Barclays, Constellation Brands and Southwest Airlines
Allergan Plc Chief Executive Officer Brent Saunders received $32.8 million of compensation for 2017, a year when shares of the drugmaker slumped.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Based on readouts from this study, the company plans to evaluate the efficacy and safety of once-a-week semaglutide therapy in NASH indications in its Phase 3 trial. According to a Diabetes Care report, ~80% of NASH patients suffer from obesity.
Allergan (AGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Smart investors actively track the moves made by the titans of the hedge fund world, such as billionaire activist investor Paul Singer of Elliott Management. They know that these hedge funds manage billions of dollars’ worth of investors’ money and do extensive and costly research on stocks before they buy them. However, that doesn’t mean […]
NEW YORK, March 6, 2018 /PRNewswire/ -- CoolSculpting® teamed up with figure skating superstar and sports correspondent Johnny Weir to share his tips for looking his best at the CoolSculpting® on Ice event at The Rink at Rockefeller Center in New York City on Monday, March 5, 2018. Weir hosted an ice skating master class to discuss his life-long commitment to a healthy lifestyle, including his experience with the CoolSculpting® treatment CoolSculpting® is an FDA-cleared non-surgical, clinically proven treatment that eliminates stubborn fat using a patented cooling technology, owned by Allergan plc (AGN). Fans around the world are inspired by Weir's elegant yet edgy style, as well as the unpredictability of what he will say, wear or do.
Revance Therapeutics Inc (NASDAQ: RVNC ) has dropped 9 percent since the start of the year, but it's begun a path to redemption through a new, respected advocate. The Rating Goldman Sachs analysts Dana ...
Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.